The ERN eUROGEN Strategic Board Meeting took place on 26–27 February 2026 at the Radboudumc Experience Center in Nijmegen, the Netherlands, in a hybrid format. A total of 76 participants attended, with 34 present in person and 42 joining online.
The meeting provided a comprehensive update on activities and progress across all work packages under the 2023–2027 Direct Operational Grant. ERN eUROGEN is performing well overall: most planned targets are on track or have been exceeded, particularly in dissemination, webinars, and guideline development. The mid-term interim report was submitted in February 2026, ahead of an independent expert review by HaDEA on 27 March 2026.
Key themes discussed across the two days included strategies to increase CPMS usage and registry patient numbers, enhancements to the webinar programme, updates to the ERN eUROGEN Monitoring & Assessment Protocol, and planning for the next EU grant cycle (2028–2034).
The full meeting report will be circulated to network members shortly.
